http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 13 Aug 2026 16:21:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Bolt+Biotherapeutics%2C++++++++++++++++++Filed+by%3A+RENAISSANCE+TECHNOLOGIES+LLC/26921567.html si-local-file:///var/storage/secattach/20260813/26921567.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Bolt+Biotherapeutics%2C++++++++++++++++++Filed+by%3A+RENAISSANCE+TECHNOLOGIES+LLC/26921567.html Thu, 13 Aug 2026 16:21:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Bolt+Biotherapeutics%2C++++++++++++++++++Filed+by%3A+RENAISSANCE+TECHNOLOGIES+LLC/26921567.html si-local-file:///var/storage/secattach/20260813/26921567.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Bolt+Biotherapeutics%2C++++++++++++++++++Filed+by%3A+RENAISSANCE+TECHNOLOGIES+LLC/26921567.html Thu, 13 Aug 2026 16:21:00 -0400 BOLT O.49824918 http://www.streetinsider.com/Earnings/Bolt+Biotherapeutics+%28BOLT%29+Misses+Q2+EPS+by+124c/26906916.html <p>Bolt Biotherapeutics (NASDAQ: BOLT) reported Q2 EPS of ($4.57), $1.24 worse than the analyst estimate of ($3.33). Revenue for the quarter came in at $5 thousand versus the consensus estimate of $1.5 million.</p><p>For earnings history and earnings-related data on Bolt Biotherapeutics (BOLT) <a href="http://www.streetinsider.com/ec_earnings.php?q=BOLT">click here</a>.</p> http://www.streetinsider.com/Earnings/Bolt+Biotherapeutics+%28BOLT%29+Misses+Q2+EPS+by+124c/26906916.html Tue, 11 Aug 2026 17:04:58 -0400 BOLT http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+30/26905681.html si-local-file:///var/storage/secattach/20260811/26905681.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+30/26905681.html Tue, 11 Aug 2026 16:07:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+30/26905681.html si-local-file:///var/storage/secattach/20260811/26905681.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+30/26905681.html Tue, 11 Aug 2026 16:07:00 -0400 BOLT O.49824918 http://www.streetinsider.com/Press+Releases/Bolt+Biotherapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905567.html <ul><li>First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt&apos;s 3Q 2026 results<br/></li><li>Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027<br/></li></ul> <p>REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.</p> <p>“In the second quarter, we continued to make meaningful progress in the ongoing BDC-4182 Phase 1/2 study in http://www.streetinsider.com/Press+Releases/Bolt+Biotherapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905567.html Tue, 11 Aug 2026 16:05:00 -0400 BOLT O.49824918 http://www.streetinsider.com/Press+Releases/Bolt+Biotherapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905567.html <ul><li>First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt&apos;s 3Q 2026 results<br/></li><li>Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027<br/></li></ul> <p>REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.</p> <p>“In the second quarter, we continued to make meaningful progress in the ongoing BDC-4182 Phase 1/2 study in http://www.streetinsider.com/Press+Releases/Bolt+Biotherapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905567.html Tue, 11 Aug 2026 16:05:00 -0400 BOLT O.49824918 http://www.streetinsider.com/Globe+Newswire/Bolt+Biotherapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905567.html <ul><li>First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt&apos;s 3Q 2026 results<br/></li><li>Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027<br/></li></ul> <p>REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.</p> <p>“In the second quarter, we continued to make meaningful progress in the ongoing BDC-4182 Phase 1/2 study in http://www.streetinsider.com/Globe+Newswire/Bolt+Biotherapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905567.html Tue, 11 Aug 2026 16:05:00 -0400 BOLT O.49824918 http://www.streetinsider.com/Globe+Newswire/Bolt+Biotherapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905567.html <ul><li>First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt&apos;s 3Q 2026 results<br/></li><li>Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027<br/></li></ul> <p>REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.</p> <p>“In the second quarter, we continued to make meaningful progress in the ongoing BDC-4182 Phase 1/2 study in http://www.streetinsider.com/Globe+Newswire/Bolt+Biotherapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26905567.html Tue, 11 Aug 2026 16:05:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Bolt+Biotherapeutics%2C+++++For%3A+Aug+11/26905590.html si-local-file:///var/storage/secattach/20260811/26905590.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Bolt+Biotherapeutics%2C+++++For%3A+Aug+11/26905590.html Tue, 11 Aug 2026 16:05:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Bolt+Biotherapeutics%2C+++++For%3A+Aug+11/26905590.html si-local-file:///var/storage/secattach/20260811/26905590.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Bolt+Biotherapeutics%2C+++++For%3A+Aug+11/26905590.html Tue, 11 Aug 2026 16:05:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+Berner+Laura/26635839.html si-local-file:///var/storage/secattach/20260611/26635839.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+Berner+Laura/26635839.html Thu, 11 Jun 2026 16:15:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+Berner+Laura/26635839.html si-local-file:///var/storage/secattach/20260611/26635839.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+Berner+Laura/26635839.html Thu, 11 Jun 2026 16:15:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+LAPORTE+KATHLEEN/26635804.html si-local-file:///var/storage/secattach/20260611/26635804.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+LAPORTE+KATHLEEN/26635804.html Thu, 11 Jun 2026 16:14:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+LAPORTE+KATHLEEN/26635804.html si-local-file:///var/storage/secattach/20260611/26635804.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+LAPORTE+KATHLEEN/26635804.html Thu, 11 Jun 2026 16:14:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+Dupont+Jakob/26635760.html si-local-file:///var/storage/secattach/20260611/26635760.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+Dupont+Jakob/26635760.html Thu, 11 Jun 2026 16:12:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+Dupont+Jakob/26635760.html si-local-file:///var/storage/secattach/20260611/26635760.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+Dupont+Jakob/26635760.html Thu, 11 Jun 2026 16:12:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+O%26apos%3BCALLAGHAN+BRIAN/26635735.html si-local-file:///var/storage/secattach/20260611/26635735.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+O%26apos%3BCALLAGHAN+BRIAN/26635735.html Thu, 11 Jun 2026 16:10:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+O%26apos%3BCALLAGHAN+BRIAN/26635735.html si-local-file:///var/storage/secattach/20260611/26635735.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+O%26apos%3BCALLAGHAN+BRIAN/26635735.html Thu, 11 Jun 2026 16:10:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+ONETTO+NICOLE/26635668.html si-local-file:///var/storage/secattach/20260611/26635668.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+ONETTO+NICOLE/26635668.html Thu, 11 Jun 2026 16:07:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+ONETTO+NICOLE/26635668.html si-local-file:///var/storage/secattach/20260611/26635668.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+10++Filed+by%3A+ONETTO+NICOLE/26635668.html Thu, 11 Jun 2026 16:07:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+11/26635614.html si-local-file:///var/storage/secattach/20260611/26635614.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+11/26635614.html Thu, 11 Jun 2026 16:05:00 -0400 BOLT O.49824918 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+11/26635614.html si-local-file:///var/storage/secattach/20260611/26635614.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Bolt+Biotherapeutics%2C+++++For%3A+Jun+11/26635614.html Thu, 11 Jun 2026 16:05:00 -0400 BOLT O.49824918 http://www.streetinsider.com/New+Coverage/Rodman+%26+Renshaw+Starts+Bolt+Biotherapeutics%2C+Inc.+%28BOLT%29+at+Buy/26566426.html <p>Rodman & Renshaw analyst Michael King Jr. initiates coverage on Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) with a Buy rating and a price target of $22.00.</p><p>The analyst comments "We are initiating coverage of Bolt Biotherapeutics with a BUY rating and $22 price target based on the company's first-in-class Claudin 18.2 immune-stimulating antibody conjugate (ISAC) platform, a near-term 3Q26 clinical readout from BDC-4182, and an enterprise value that ascribes essentially zero worth to a pipeline of therapeutic modalities that could redefine how the immune system is directed against solid tumors."</p><p>For an analyst ratings summary and ratings history on Bolt Biotherapeutics, Inc. <a http://www.streetinsider.com/New+Coverage/Rodman+%26+Renshaw+Starts+Bolt+Biotherapeutics%2C+Inc.+%28BOLT%29+at+Buy/26566426.html Thu, 28 May 2026 16:17:15 -0400 BOLT http://www.streetinsider.com/Analyst+Comments/Rodman+%26+Renshaw+Starts+Bolt+Biotherapeutics%2C+Inc.+%28BOLT%29+at+Buy/26566426.html <p>Rodman & Renshaw analyst Michael King Jr. initiates coverage on Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) with a Buy rating and a price target of $22.00.</p><p>The analyst comments "We are initiating coverage of Bolt Biotherapeutics with a BUY rating and $22 price target based on the company's first-in-class Claudin 18.2 immune-stimulating antibody conjugate (ISAC) platform, a near-term 3Q26 clinical readout from BDC-4182, and an enterprise value that ascribes essentially zero worth to a pipeline of therapeutic modalities that could redefine how the immune system is directed against solid tumors."</p><p>For an analyst ratings summary and ratings history on Bolt Biotherapeutics, Inc. <a http://www.streetinsider.com/Analyst+Comments/Rodman+%26+Renshaw+Starts+Bolt+Biotherapeutics%2C+Inc.+%28BOLT%29+at+Buy/26566426.html Thu, 28 May 2026 16:17:15 -0400 BOLT